Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials

Nature Clinical Practice Oncology

Volumn 3, Issue 12, 2006, Pages 658-667

  Fleming, Mark T ^a   Morris, Michael J ^b   Heller, Glenn ^c   Scher, Howard I ^b,d  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Sidney Kimmel Center for Prostate and Urologic Cancers   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CALCITRIOL; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HYDROCORTISONE; KALLIKREIN; LACTATE DEHYDROGENASE; LEUPRORELIN; LEXIDRONAM SAMARIUM SM 153; MITOXANTRONE; NILUTAMIDE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89; SURAMIN; TESTOSTERONE; ZOLEDRONIC ACID;

ANTIGEN PRESENTING CELL; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG RESEARCH; DRUG WITHDRAWAL; ECHOGRAPHY; HUMAN; KARNOFSKY PERFORMANCE STATUS; METASTASIS POTENTIAL; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN FAMILY; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

CLINICAL TRIALS; ENDPOINT DETERMINATION; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33751558449     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0664     Document Type: Review

References (57)

1. Scher HI and Heller G (2000) Clinical states in prostate cancer: Towards a dynamic model of disease progression. Urology 55: 323-327
2. Thompson IM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224
3. Beatty PA (2004) Prostate cancer with low PSA levels. N Engl J Med 351: 1802-1803
4. Thompson IM et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350: 2239-2246
5. D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135
6. Kattan MW et al. (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771
7. Kattan MW et al. (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18: 3352-3359
8. Partin AW et al. (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114
9. D'Amico AV et al. (2004) Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 96: 509-515
10. D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376-1383
11. D'Amico AV et al. (2003) Cancer specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. J Natl Cancer Inst 95: 1376-1383
12. Scher HI et al. (2004) Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: recommendations from the prostate-specific antigen working group. J Clin Oncol 22: 537-556
13. Smith MR et al. (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23: 2918-2925
14. Scher HI et al. (1996) Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 88: 1623-1634
15. Pound CR et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597
16. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512
17. Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
18. Yagoda A et al. (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cisdiamminedichloride platinum II. Cancer 44: 1553-1562
19. Yagoda A (1983) Cytotoxic agents in prostate cancer: An enigma. Semin Urol 1: 311-321
20. Scher HI et al. (1989) Cytotoxic chemotherapy in advanced carcinoma of the prostate: Memorial Sloan-Kettering Cancer Center experience. In Systemic Therapy for Genitourinary Tumors, 228-233 (Eds Johnson DE et al.) Chicago: Year Book Medical Publishers
21. Bubley GJ et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the PSA Working Group. J Clin Oncol 17: 3461-3467
22. Therasse P et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
23. Scher HI et al. (2005) Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 11: 5223-5232
24. Figg WD et al. (1996) Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 14: 513-517
25. Fleming TR et al. (1997) Surrogate endpoints. AIDS Clin Rev 129-143
26. Guise TA and Mundy GR (1998) Cancer and bone. Endocr Rev 19: 18-54
27. Ferro MA et al. (1989) High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of prostate-specific antigen to monitor response. Urology 34: 134-138
28. Scher HI et al. (1990) Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8: 1830-1838
29. Kelly WK et al. (1993) Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol 11: 607-615
30. Prentice RL (1989) Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8: 431-440
31. Fleming TR and DeMets DL (1996) Surrogate end points in clinical trials: are we being misled. Ann Intern Med 125: 605-613
32. Scher HI et al. (1999) Post-therapy serum prostate specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91: 244-251
33. Smith DC et al. (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835-1843
34. Fossa SD et al. (2001) Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19: 62-71
35. Thalmann GN et al. (1996) Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88: 794-801
36. Sridhara R et al. (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13: 2944-2953
37. Verbel DA et al. (2002) Quantifying the amount of variation in survival explained by PSA. Clin Cancer Res 8: 2576-2579
38. Petrylak DP et al. (2004) SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA) [abstract #3]. J Clin Oncol 22
39. Roessner M et al. (2005) Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer [abstract #4554]. Proc Am Clin Oncol 23: S391
40. Petrylak D et al.: Evaluation of post treated on SWOG 99-16. JNCI, in press
41. Jain RK et al. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40
42. Schatzkin A and Gail M (2002) The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2: 19-27
43. Strother JM et al. (2005) A phase II trial of weekly high-dose calcitriol and docetaxel in patients with locally advanced or metastatic pancreatic adenocarcinoma [abstract #94]. Proc Am Clin Oncol 23
44. Balk SP et al. (2003) Biology of prostate-specific antigen. J Clin Oncol 21: 383-391
45. Fortier AH et al. (1999) Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 91: 1635-1640
46. Miyata Y et al. (2003) Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54: 125-132
47. Denmeade SR et al. (2003) Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54: 249-257
48. Shah RB et al. (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 64: 9209-9216
49. Beer TM et al. (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21: 123-128
50. Beer TM et al. (2004) Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 13: 2225-2232
51. Small EJ et al. (2005) Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): Final survival data from a phase 3 randomized placebo-controlled trial [abstract #264]. Proc Multidisciplinary Prostate Cancer Symposium
52. Saad F et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468
53. Johnson JR et al. (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21: 1404-1411
54. Kelly WK et al. (2000) The development of biologic endpoints in patients treated with differentation agents: An experience with retinoids in prostate cancer. Clin Cancer Res 6: 838-846
55. Stephan C et al. (2006) Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: An update. Clin Chem 52: 59-64
56. Sartor O et al. (1998) Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52: 252-256
57. Small EJ et al. (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18: 1440-1450